🇺🇸 FDA
Patent

US 10028932

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

granted A61KA61K31/352A61K31/366

Quick answer

US patent 10028932 (Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders) held by Amazentis SA expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amazentis SA
Grant date
Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K31/352, A61K31/366, A61K31/7048, A61K36/185